Profund Advisors LLC Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Profund Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 55.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,402 shares of the biopharmaceutical company’s stock after buying an additional 5,132 shares during the quarter. Profund Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $3,500,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $26,000. Altitude Crest Partners Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $30,000. Robeco Institutional Asset Management B.V. grew its holdings in Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares during the period. Finally, V Square Quantitative Management LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $52,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CMO Pushkal Garg sold 2,103 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $485,771.97. Following the completion of the sale, the chief marketing officer now directly owns 15,609 shares in the company, valued at approximately $3,605,522.91. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The disclosure for this sale can be found here. Insiders sold 70,698 shares of company stock valued at $18,497,434 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.9 %

ALNY opened at $273.88 on Monday. The stock has a fifty day moving average price of $260.11 and a 200 day moving average price of $199.42. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The stock has a market cap of $34.64 billion, a price-to-earnings ratio of -102.19 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter in the prior year, the firm earned ($2.21) earnings per share. The firm’s quarterly revenue was up 107.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Bank of America raised their price objective on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Leerink Partners upped their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday, June 25th. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Finally, Raymond James upped their target price on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.